Search
IO-202
go.drugbank.com/drugs/DB17548InvestigationalIO-202 is a first-in-class antibody targeting the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB) member 4 (LILRB4).[A257276] It is being investigated in cancers.
Prinomastat
go.drugbank.com/drugs/DB05100InvestigationalPrinomastat is a synthetic hydroxamic acid derivative with potential antineoplastic activity.
Allogenic Donor CD362-enriched Human Umbilical Cord-derived Mesenchymal Stem Cells
go.drugbank.com/drugs/DB15731InvestigationalEnrichment of CD362 expression in MSCs is being investigated for its role in immune modulation of injured tissue. … The isolated cells are expanded in culture and are able to be used allogenically -- meaning that one donor’s cells can be given to other unrelated patients.
Influenza B virus B/Brisbane/60/2008 antigen (UV, formaldehyde inactivated)
go.drugbank.com/drugs/DB10598ApprovedWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza B virus B/Phuket/3073/2013 antigen (UV, formaldehyde inactivated)
go.drugbank.com/drugs/DB10599ApprovedWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/South Australia/55/2014 IVR-175 (H3N2) antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB10601ApprovedWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza B virus B/Phuket/3073/2013 antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB10602ApprovedWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/California/7/2009 (H1N1) recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB10773ApprovedInvestigationalWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB10791ApprovedInvestigationalWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB10794ApprovedInvestigationalWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.